Originalien 1 2 Z Rheumatol 2017 · 76:528–534 Y. H. Lee · S.-C. Bae DOI 10.1007/s00393-016-0133-z Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Published online: 16 June 2016 Korea © Springer-Verlag Berlin Heidelberg 2016 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Eﬃcacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis Meta-analysis of randomized controlled trials of CZP to 14 days and may increase Introduction Methods the preferential distribution of CZP to Rheumatoid arthritis (RA) is a systemic inﬂamed tissues . Identiﬁcation of eligible studies autoimmune disease characterized by Several clinical trials have attempted and data extraction chronic synovial joint inﬂammation, to evaluate the eﬃcacy and safety of which leads to disability and loss of CZP + MTX in patients with active RA We performed an exhaustive literature quality of life [1, 2]. Tumor necrosis who had an incomplete response to MTX search using PubMed, EMBASE, and factor-α (TNF-α) is a potent pro-inﬂam- ordisease-modifyingantirheumaticdrug theCochraneControlled Trials Regis- matory cytokine that plays an important (DMARD) [9–14]. A previous meta- ter to identify available articles (up to role in
Zeitschrift für Rheumatologie – Springer Journals
Published: Jun 16, 2016
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera